Development
Alnylam Pharmaceuticals, Inc.
ALNY
$300.83
-$7.17-2.33%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -137.87M | 147.75M | -276.02M | -174.10M | -207.49M |
| Total Depreciation and Amortization | 23.97M | 23.53M | 23.45M | 26.08M | 24.89M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 77.31M | 162.60M | 129.01M | 67.68M | 64.31M |
| Change in Net Operating Assets | 6.79M | 25.53M | 64.58M | -86.14M | -13.68M |
| Cash from Operations | -29.80M | 359.41M | -58.99M | -166.48M | -131.98M |
| Capital Expenditure | -15.31M | -17.09M | -15.92M | -13.89M | -21.64M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -225.35M | 6.33M | 7.21M | -62.33M | -118.28M |
| Cash from Investing | -240.66M | -10.76M | -8.71M | -76.22M | -139.91M |
| Total Debt Issued | -- | -- | -- | -- | -777.00K |
| Total Debt Repaid | -- | -- | -- | -- | 0.00 |
| Issuance of Common Stock | 30.89M | 24.81M | 49.39M | 42.37M | 56.71M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 8.33M | 8.33M | 4.00M | 4.00M | 7.50M |
| Cash from Financing | 39.23M | 33.14M | 53.39M | 46.37M | 63.44M |
| Foreign Exchange rate Adjustments | 10.90M | -6.55M | -130.00K | 2.18M | 1.62M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -220.33M | 375.23M | -14.44M | -194.15M | -206.83M |